Biofarm registered a turnover of 263.2 million lei in the first nine months of 2025, with a net profit of 87.06 million lei, continuing the upward trend.

The Romanian pharmaceutical manufacturer Biofarm reported remarkable financial results for the first nine months of 2025, with a turnover of 263.2 million lei, an increase of 14% compared to the same period in 2024. Net profit rose from 73.25 million lei in 2024 to 87.06 million lei in 2025, and EBITDA increased by 16%, reaching 109 million lei. The company launched two new products, Biofen Plus and Magnefort B6, and will focus its strategy on optimizing production, international expansion, and investment in innovation.

Biofarm, a leader in the Romanian market in several product categories, owns two factories in Bucharest and a diversified portfolio of over 100 products, covering 65 therapeutic areas. The CEO, Cătălin Vicol, emphasized the company's commitment to sustainable growth and adapting to consumer demands.